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Abstract
The hepatocyte growth factor receptor (c-Met) and a constitutively active mutant of the epidermal growth factor
receptor (ΔEGFR/EGFRvIII) are frequently overexpressed in glioblastoma (GBM) and promote tumorigenesis. The
mechanisms underlying elevated hepatocyte growth factor (HGF) production in GBM are not understood. We found
higher, coordinated mRNA expression levels of HGF and c-Met in mesenchymal (Mes) GBMs, a subtype associated
with poor treatment response and shorter overall survival. In an HGF/c-Met–dependent GBM cell line, HGF expression
declined upon silencing of c-Met using RNAi or by inhibiting its activity with SU11274. Silencing c-Met decreased
anchorage-independent colony formation and increased the survival of mice bearing intracranial GBM xenografts.
Consistent with these findings, c-Met activation by ΔEGFR also elevated HGF expression, and the inhibition of ΔEGFR
with AG1478 reduced HGF levels. Interestingly, c-Met expression was required for ΔEGFR-mediated HGF production,
anchorage-independent growth, and in vivo tumorigenicity, suggesting that these pathways are coupled. Using an
unbiased mass spectrometry–based screen, we show that signal transducer and activator of transcription 3 (STAT3)
Y705 is a downstream target of c-Met signaling. Suppression of STAT3 phosphorylation with WP1193 reduced HGF
expression in ΔEGFR-expressing GBM cells, whereas constitutively active STAT3 partially rescued HGF expression
and colony formation in c-Met knockdown cells expressing ΔEGFR. These results suggest that the c-Met/HGF signal-
ing axis is enhanced by ΔEGFR through increased STAT3-dependent HGF expression and that targeting c-Met in Mes
GBMs may be an important strategy for therapy.
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Introduction
Hepatocyte growth factor receptor (c-Met), a receptor tyrosine kinase,
is typically expressed on epithelial cells and activated in a para-
crine manner by its mesenchymal–derived ligand, hepatocyte growth
factor (HGF) [1,2]. However in glioblastoma (GBM), which is the
most common and aggressive form of adult brain cancer [3], c-Met
and HGF are frequently coexpressed and function in an autocrine
signaling loop [4–6]. Moreover, the coexpression of c-Met and HGF
in GBM accrues with tumor grade [7,8]. When c-Met or HGF are
inhibited in vivo, a dramatic reduction in GBM tumor formation
and growth occurs, underscoring the importance of the c-Met/HGF
axis in GBMs [9]. In addition to activating c-Met, HGF increases
the transcription of the c-Met gene in GBM cells [10]. This feed-
forward loop of c-Met/HGF dysregulation most likely contributes to
c-Met overexpression.
For GBM patients, shorter overall survival is associated with high-
level c-Met expression [11], raising the question of how this fits with the
recently identified prognostic GBM subtypes that have been identified
using gene expression classifiers [3,12]. Of these, the mesenchymal
(Mes) GBM subtype is associated with aggressive disease, a poor prog-
nosis [3,13], and chemotherapy resistance [14]. Interestingly, recurrent
tumors shift their molecular profiles toward Mes signatures, which
include signal transducer and activator of transcription 3 (STAT3)
expression [3], a transcription factor required for c-Met signaling and
tumorigenesis [15], and prompting our investigation of direct links
between GBM subtype and c-Met pathway activity.
Not only is c-Met overexpressed in GBM [5], but it is also often
hyperactivated in other cancers [16]. It has been shown that trans-
activation of c-Met by the epidermal growth factor receptor (EGFR)
is an important contributing factor to aberrant c-Met signaling [17–
19] and depends on the direct association with active EGFR [20].
In GBMs, approximately 40% of tumors overexpressing wild-type
EGFR coexpress a 2- to 7-exon deletion mutant of the EGFR,
known as the ΔEGFR or EGFRvIII [21]. This cancer-specific mutant
signals constitutively at a low level in a ligand-independent manner,
owing to inefficient receptor dimerization [22–24], internalization,
and down-regulation [25,26]. ΔEGFR is a key mediator of apoptotic
resistance through increased BCL-XL expression [27,28], which
significantly enhances the tumorigenicity of GBM cells in vivo
[25,28,29]. In the clinical setting, ΔEGFR expression has also been
associated with poor patient survival [30–32]. Recent studies have
shown that that the phosphorylation of Y1234, a requirement of
c-Met activity, is highly responsive to titrated levels of ΔEGFR in
glioma cells [33]. Notably, c-Met Y1234 is markedly increased in
ΔEGFR-overexpressing cells compared to cells expressing kinase-
inactive ΔEGFR, wild-type EGFR, or wild-type EGFR stimulated with
EGF [34]. These reports highlight the significance of cross talk between
receptor tyrosine kinases as one of the major mechanisms for their
dysregulation in cancers [16].
Biologic processes that lead to the deregulation of c-Met expres-
sion and activation in tumors have been extensively investigated
[16]. However, mechanisms governing aberrant HGF upregulation
in GBM have not yet been identified. In our study, we show that
c-Met and HGF expression is upregulated and coexpressed in
Mes GBMs. We found that ΔEGFR regulates the expression of
HGF through c-Met in GBM cells and that c-Met was not only critical
for HGF production but also for ΔEGFR-mediated tumorigenicity.
Further, we identified STAT3 as one of the downstream modulators
of c-Met–mediated HGF expression in GBM cells.
Materials and Methods
Cell Culture
U87 and LN18 human GBM cells were purchased from the
American Type Culture Collection (Manassas, VA) and cultured as pre-
viously described [34].MDCK cells [gift fromDr Zhimin Lu, University
of Texas MD Anderson Cancer Center (UTMDACC)], human em-
bryonic kidney 293FT (HEK 293FT) cells (gift from Dr Howard
Colman, UTMDACC), and GP2-293 cells (Clontech, Mountain View,
CA) were cultured in Dulbecco’s modified Eagle’s medium (10% FBS)
at 5% CO2 and 37°C.
Antibodies and Reagents
The following primary antibodies were used: anti–c-Met, anti–
pc-Met (Y1234/Y1235); anti-EGFR, anti-pEGFR (Y1173), anti-
STAT3, and anti-pSTAT3 (Y705) (Cell Signaling Technology,
Danvers, MA); anti–β-actin–HRP (Sigma-Aldrich, St Louis, MO);
anti-HGF (R&D Systems, Minneapolis, MN); anti-mouse secondary
antibody (Fisher Scientific, Pittsburgh, PA); anti-rabbit secondary anti-
body (Jackson ImmunoResearch Laboratories Inc, West Grove, PA).
The following reagents were used: recombinant human HGF (rhHGF;
Chemicon, Billerica, MA); SU11274 and AG1478 (Calbiochem,
San Diego, CA); hygromycin B, G418, and puromycin (Fisher
Scientific); WP1193 (gift from Dr Waldemar Priebe; UTMDACC).
Cell Lysate Preparation and Western Blot Analysis
Cell lysates were prepared as previously described [34]. For Western
blot analysis, 20 to 30 μg of protein was separated on 4% to 12%
Bis-Tris NuPage gels (Invitrogen, Carlsbad, CA), except for HGF
analysis that used 150 to 200 μg of protein lysate.
Transfection or Viral Transduction
HEK 293FT cells were transfected with short hairpin RNA (shRNA)
targeting c-Met or nontargeting scrambled shRNA (pLK0.1), pCMV-
dR8.2dvpr, and pCMV-VSVG (gifts fromDrTa-Jen Liu, UTMDACC)
using Fugene HD (Roche, Indianapolis, IN) according to the manu-
facturer’s instructions. Filtered viral supernatant was applied to U87 cells
with 8 μg/ml hexadimethrine bromide, and sh-c-Met clones were made
by limiting dilution during selection (1 μg/ml puromycin). c-Met
shRNA hairpin sequences (Open Biosystems, now Thermo Fisher
Scientific, Waltham, MA) are given as follows: TRCN0000009850
(sh-c-Met#A) and TRCN0000040047 (sh-c-Met#B); sh-c-Met#A:
sense, 5′-CAGAATGTCATTCTACATGAG-3′; sh-c-Met#A: anti-
sense, 5′-CTCATGTAGAATGACATTCTG-3′; sh-c-Met#B: sense,
5′-GCCAGCCTGAATGATGACATT-3′; sh-c-Met#B: antisense,
5′-AATGTCATCATTCAGGCTGGC-3′.
pLRNL-ΔEGFR (gift from Dr H-J Huang, The University of
California, San Diego) was packaged into viral particles using GP2
cells, pCMV-VSVG, and Lipofectamine 2000 (Invitrogen). Viral
supernatant was used to infect U87 GBM cells and later selected with
G418 (2.5 μg/ml).
Constitutively active STAT3 (STAT3-CA) in pcDNA3.1/Hygro(+)
(gift from Dr Robert Arceci, John Hopkins University School of
Medicine) or pcDNA3.1/Hygro(+) empty vector (gift from Dr Suyun
Huang, UTMDACC) was used to transfect U87 ΔEGFR or U87 sh-c-
Met#B2ΔEGFRusing FugeneHD (Roche) and then selected (50 μg/ml
hygromycin B).
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Quantitative Real-Time Polymerase Chain Reaction
mRNA was extracted from cells using Qiagen’s RNeasy Mini
Kit. Reverse transcription was performed using Bio-Rad’s iScript
cDNA Synthesis Kit. Quantitative real-time polymerase chain
reaction (PCR) was performed using FastStart SYBR Green
Master reagent (Roche) with the following primers: HGF
(forward): 5′-CTCACACCCGCTGGGAGTAC-3′; HGF (reverse):
5′-TCCTTGACCTTGGATGCATTC-3′; β2-microglobulin
(forward): 5′-ATCCATCCGACATTGAAGTT-3′; β2-microglobulin
(reverse): 5′-GGCAGGCATACTCATCTTTT-3′. Data were normal-
ized to internal β2-microglobulin.
HGF ELISA
Conditioned media (CM) was collected from 80% confluent
24-hour serum-starved cells. Plates were coated with mouse anti-
human HGF monoclonal antibody (0.5 μg/ml; R&D Systems) or
isotype control antibody. Dried wells were washed with phosphate-
buffered saline containing 0.05% Tween 20, blocked with 50 mM Tris
(pH 8.0) containing 0.14MNaCl, 1% BSA, and 0.05%Tween 20, and
rewashed. CM (concentrated using Millipore 30,000-kD cellulose ultra-
filtration membranes) or HGF standard was serially diluted in TBS
containing 0.1% BSA and 0.05% Tween 20 (pH 7.3) and applied to
plate wells. After washing, goat anti-human HGF polyclonal antibody
(0.5 μg/ml; R&D Systems) was added. Washed wells were incu-
bated with HRP-conjugated bovine anti-goat IgG (40 ng/ml; Jackson
ImmunoResearch Laboratories Inc). QuantaBlu Fluorogenic Per-
oxidase Substrate (Thermo Fisher Scientific) was applied to washed
wells, and the reactions were terminated using QuantaBlu Stop Solu-
tion (Thermo Fisher Scientific). Fluorescence (excitation = 325 and
emission = 420) was measured using a SpectraMax Gemini (Molecu-
lar Probes, now Invitrogen) fluorescent plate reader and SOFTmax
Pro (v.3.0).
Anchorage-Independent Growth Assays
For anchorage-independent growth assays, 7.5 × 102 cells/well
(24-well plate; Figure 3A ) or 1.5 × 103 cells/well (12-well plate;
Figure 7C ) were cultured three-dimensionally, and colony numbers
were counted as described previously [35].
Xenograft Studies
Survival curves were generated after 2 × 105 cells per 5 μl were
stereotactically injected into the right frontal lobe of 10-week-old
nu/nu mice; animal experiments were performed on the same day.
One U87 sh-c-Met#A2 mouse died within 48 hours of injection
because of procedural stress. The maintenance and care of mice
were conducted in accordance with Laboratory Animal Resources
Figure 1. Enhanced HGF and c-Met expression associate withMes GBM. (A) HGF and c-Met mRNA expression correlate in GBMs (n= 495;
Spearman correlation: r = 0.5199; P < .0001). (B) GBMs were assigned to a GBM subtype, from gene lists detailed by Verhaak et al. [12],
based on highest average z-score normalized metagene scores. c-Met mRNA expression was then documented per tumor [n= 495; Tukey
box plot; t tests: ***P< .0001; mesenchymal (Mes); proneural (PN); neural (Nrl); classical (Cl)]. (C) HGFmRNA expression was reported for
tumors in A (n= 495; Tukey box plot; t tests: ***P< .0001). (D) HGF and c-Met mRNA expression correlate in Mes GBM tumors (n= 148;
Spearman correlation: r = 0.3965; P ≤ .0001).
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Commission standards under an approved protocol (100712131) in
MD Anderson’s Animal Facility.
Immunoprecipitation Assays
c-Met immunoprecipitation and subsequent immunoblot analysis
techniques were performed as previously described [34].
Mass Spectrometry
Samples for mass spectrometry (MS) analysis were prepared and
analyzed as previously described [34]. Liquid chromatography (LC)-MS
analysis was performedwith Agilent’s 6340 Ion Trap Systemwith electron
transfer dissociation capability, where fragmentation alternated between
collision-induced dissociation and electron transfer dissociation modes.
MS/MS spectra were extracted using Bruker CompassXport to
“.mzxml” files and converted to “.mgf ” files for database searches using
Trans-Proteomic Pipeline (Seattle Proteome Center, Seattle, WA).
Mascot search engine (v.2.3.02) searched human Swiss-Prot database’s
proteins to identify peptides and modifications. Phosphorylation site
assignments were manually confirmed. Ideal-Q [36] software aligned
the runs based on retention time, and phosphopeptide peak areas were
manually calculated. Values were normalized to the total ion current of
the whole run; phosphopeptide mean peak areas were then calculated.
The Cancer Genome Atlas Analyses
Level 3 gene expression data (Agilent 244K custom gene expres-
sion chip) were downloaded as log10 ratios to a Universal Human
Reference RNA (Stratagene, La Jolla, CA) from 495 GBM tumors
from The Cancer Genome Atlas (TCGA) data portal (http://tcga-
data.nci.nih.gov/tcga/tcgaHome2.jsp) on 15 July 2011.
Gene lists defined by Verhaak et al. [12] for each GBM subtype
were used to calculate average GBM subtype metagene scores for
each tumor. The highest z-score normalized average metagene score
was used for GBM subtype assignment.
Statistical Analysis
Data significance was analyzed using GraphPad Prism 5.03 software.
For specific tests of significance, please refer to figure legends. All t tests
were unpaired and two-tailed.
Figure 2. c-Met activity modulates HGF expression. (A) Quantitative real-time PCR measured HGF mRNA levels in U87 clones expressing
two different c-Met lentiviral shRNA; 10% FBS–containing media (t test compared with sh-control: **P < .005, *P < .05; n = 3 ± SEM;
at least duplicate samples per experiment). (B) Western blot analysis of HGF expression in cells detailed in A. (C) ELISA quantification of
HGF in CM from control versus U87 sh-c-Met clones (one-way analysis of variance; Dunnett multiple comparison test: *P < .05; trip-
licate technical repeats above background analyzed per experiment; n = 2 ± SEM). (D) HGF quantitative real-time PCR of U87 cells
treated with 10 μM SU11274 (16 hours); 10% FBS–containing media (t test compared with 0.1% DMSO control: *P < .05; n = 4 ± SEM;
at least duplicate samplesper experiment). (E)Westernblot analysis ofHGFandc-Met activity after 0.1%DMSOor10μMSU11274 treatment
(16 hours); 10% FBS–containing media.
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Results
c-Met and HGF Coexpression in Mes GBM
Analysis of a large data set of 495 GBM tumors (gene expression data
from the Agilent platform) from the TCGA Network database [37]
showed that c-Met and HGF transcripts are frequently coexpressed
(Figure 1A), validating previous smaller studies [5,6,8].
To assess GBM subtype–specific c-Met and HGF mRNA expres-
sion, we stratified the GBM tumors from the TCGA database
according to their highest z-score corrected subtype-specific meta-
gene scores. These scores were calculated using centroid-based gene
lists that have previously been described for GBM subtypes [12]. We
found that both c-Met (Figure 1B ) and HGF (Figure 1C ) mRNA
expression were significantly higher in Mes GBMs when compared
with proneural (PN), neural (Nrl), and classical (Cl) GBM subtypes
(P < .0001). No discernible differences were found between the PN,
Nrl, and Cl subtypes. Consistently, in 200 GBMs that Verhaak
et al. [12] had assigned to subtypes, we found that c-Met and HGF
mRNA expression were highest in Mes GBMs (Figure W1, A and
B ). Furthermore, we found that the expression of HGF and c-Met
correlated significantly in the 148 Mes GBM tumors (Figure 1D;
Spearman correlation; r = 0.3965; P < .0001). These data suggest that
c-Met and HGF may be co-regulated in Mes GBM and contribute to
their biology.
To validate our findings in an independent data set, we used
Verhaak et al.’s [12] subtype-specific gene expression classifier lists to
assign GBMs in the Repository for Molecular Brain Neoplasia Data
(REMBRANDT) database (Affymetrix gene expression platform) to a
particular GBM subtype. After determining HGF and c-Met mRNA
expression levels per GBM, we found a similar trend of increased
c-Met and HGF expression in Mes GBMs (Figure W1, C and D).
Phillips et al. assigned GBMs to specific subtypes based on prog-
nostic gene expression lists [3]. Patients survived longer if their
tumors had a PN signature but had the worst prognosis if their
tumors were classified as Mes. Using gene lists for GBM subtype
assignment (n = 495) of Phillips et al. [3], we found that c-Met
and HGF expression was lower in PN tumors when compared with
the more aggressive Mes or proliferative tumors, suggesting that the
survival of GBM patients may be impacted with enhanced c-Met/
HGF expression (Figure W1, E and F ).
c-Met Modulates HGF Expression
The coincident elevation of HGF and c-Met mRNA in GBM may
be caused by a positive regulatory loop that functions to enhance
tumorigenesis. Because c-Met activation by HGF has been reported
to induce c-Met expression in GBM [10], we hypothesized that
c-Met may also positively modulate the expression of its own ligand.
The human U87 GBM cell line coexpresses c-Met and HGF and
is dependent on c-Met signaling for proliferation and survival
[38,39]. shRNA-mediated knockdown of c-Met in U87 cells
decreased steady-state amounts of HGF mRNA (Figure 2A ). This
correlated with reduced levels of HGF protein by Western blot
analysis (Figure 2B ) as well as attenuated levels of secreted HGF as
evidenced by ELISA (Figure 2C ).
Given that HGF expression is regulated by c-Met, we asked
whether c-Met’s kinase activity was necessary for this. Treatment of
two c-Met–dependent GBM cell lines, U87 [39] and LN18 [5], with
SU11274, a specific c-Met inhibitor [40], decreased HGF mRNA
and protein amounts in U87 (Figure 2, D and E ) and LN18 cells
(Figure W2 and Table W1). Taken together, these results suggest a
feedback mechanism in which c-Met can regulate HGF expression
through activated c-Met signaling.
c-Met Is Required for Anchorage-Independent Growth and
Tumorigenicity of U87 Cells
We then characterized the biologic implications of c-Met silencing
in U87 cells. c-Met knockdown significantly inhibited anchorage-
independent growth of U87 cells (Figure 3A). To test the tumorigenic
potential of these cells in vivo, we injected them intracranially into
Figure 3. Biologic effects of c-Met knockdown in U87 cells. (A) Anchorage-independent growth of U87 sh-control cells compared with
U87 sh-c-Met clones (t test: *P< .05; n= 3 ± SEM; at least triplicate samples per experiment). (B) Survival curves of nude mice injected
intracranially with 2 × 105 U87 sh-control or U87 sh-c-Met clones. Median survival and significant differences are shown (log-rank test of
U87 sh-control versus U87 sh-c-Met clones).
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nude mice (Figure 3B). As expected, the U87 sh-control group
showed a short median survival (16 days; Figure 3B). In contrast,
mice that received U87 cells with c-Met knockdown did not form
tumors after 65 days. The absence of tumors was verified by micro-
scopic examination of hematoxylin and eosin (H&E)-stained serial
sections from two mouse brains per group (data not shown). Taken
together, these data suggest that c-Met is critical for in vitro colony
formation and the tumorigenicity of U87 cells.
ΔEGFR Increases HGF Expression in a c-Met
Activity–Dependent Manner
Using shotgun phosphoproteomics, we [34] and others [33] iden-
tified c-Met (Y1234) as a target of ΔEGFR signaling in GBM cells.
Therefore, we examined whether ΔEGFR could regulate HGF levels
through c-Met. Using quantitative real-time PCR, we show that
ΔEGFR upregulated HGF mRNA levels by more than two-fold
relative to parental U87 cells (Figure 4A ). Similarly, Western blot
analysis revealed that HGF protein levels increased with ΔEGFR
expression in U87 cells (Figure 4B). As expected, the activity of c-Met
increased in the presence of ΔEGFR (Figure 4B).
To determine whether the HGF produced by GBM cells was
secreted and functionally active, we examined the ability of CM from
U87ΔEGFRcells to activate c-Met (Y1234/Y1235) inHGF-responsive
MDCK cells. The addition of CM resulted in acute stimulation of
c-Met in a time-dependent manner in MDCK cells, which was com-
parable to stimulation of MDCK cells with rhHGF. Pre-neutralization
of U87 ΔEGFR CM with an anti-HGF antibody blocked c-Met
activation (Figure 4C ).
To test whether the kinase activity of ΔEGFR modulates HGF
expression, we treated U87 ΔEGFR–expressing cells with the EGFR/
ΔEGFR inhibitor AG1478 [33]. Treatment with AG1478 reduced
HGF mRNA levels. Using maximal doses of AG1478 and SU11274
that suppress the activities of ΔEGFR and c-Met, respectively, we
found that AG1478 was as effective at reducing HGF mRNA levels
as SU11274. This suggests that ΔEGFR and c-Met are likely part of
the same pathway regulating HGF expression (Figure 4D).
These results were mirrored when cellular HGF protein amounts
were investigated after treatment of ΔEGFR-expressing U87 cells
with AG1478, SU11274, or in combination (Figure 4E ). The levels
of HGF protein correlated with the activity of c-Met, as measured by
phosphorylation of Y1234/Y1235. As expected, c-Met’s tyrosine kinase
activity diminished with AG1478 treatment, which was accompanied
by a reduction in HGF protein levels. A greater reduction in both
c-Met’s activity and HGF levels were obtained with SU11274
treatment. These results are suggestive of a positive feedforward
relationship between c-Met’s activity levels and HGF induction.
ΔEGFR is predominantly expressed in Cl GBMs; however, it is
also expressed in Mes and PN GBMs [12]. As previously shown,
the Cl GBM subtype expresses lower levels of c-Met and HGF tran-
scripts to that of Mes GBMs (Figure 1, B and C , respectively). Given
the importance of the ΔEGFR in Cl GBMs, we wanted to determine
whether c-Met and HGF mRNA expression would correlate in this
subtype. Using Spearman correlation, we found that their coordinated
expression was significant (Figure W3; n = 141; r = 0.4562; P < .0001).
ΔEGFR Does Not Rescue c-Met Knockdown Phenotypes in
U87 Cells
To determine whether ΔEGFR is capable of sustaining HGF
expression in the absence of c-Met, we overexpressed ΔEGFR in
U87 sh-c-Met clones. We found that the loss of c-Met caused a signif-
icant reduction in HGF mRNA (Figure 5A) and protein (Figure 5B)
levels, suggesting that there is an absolute requirement for c-Met in
ΔEGFR-mediated HGF regulation in GBM cells.
ΔEGFR enhances the tumorigenicity of U87 GBM xenografts
[25,29], raising the possibility that its expression could overcome
the diminished tumorigenicity that we had observed following
c-Met knockdown in U87 cells. To test this, we injected U87
sh-control, U87 sh-control ΔEGFR, U87 sh-c-Met#A2 ΔEGFR,
or U87 sh-c-Met#B2 ΔEGFR cells intracranially into nude mice
and measured their survival over 65 days (Figure 5C ). As expected,
ΔEGFR decreased the median survival of nude mice when com-
pared with those injected with sh-control cells (Figure 5C ). Strik-
ingly, c-Met knockdown abrogated the tumorigenicity of U87
xenografts even when expressing ΔEGFR. H&E staining of two
mouse brains per group confirmed the absence of tumors in these
animals (data not shown). These data suggest that c-Met loss sig-
nificantly suppresses the tumorigenicity of c-Met–dependent
GBM cells and that ΔEGFR is unable to rescue this phenotype.
STAT3 Y705 Is Responsive to the c-Met Signal
To identify changes in signaling that might be responsible for
these observations, we examined the tyrosine phosphoproteome of
U87 sh-control, U87 sh-control ΔEGFR, U87 sh-c-Met#B2, and
U87 sh-c-Met#B2 ΔEGFR cells using an MS approach (for a com-
plete list of peptides that were identified, see Table W2).
The peptides showing significant decreases (P < .05) in tyrosine
phosphorylation in U87 sh-c-Met#B2 cells compared to U87 sh-
control cells, and in U87 sh-c-Met#B2 ΔEGFR cells compared to
U87 sh-control ΔEGFR cells, are listed in Figure 6A alongside their
modified tyrosine phosphorylation sites. Interestingly, all of the
proteins identified as being responsive to the c-Met signal in ΔEGFR-
expressing cells were found to change significantly with c-Met knock-
down in parental cells. Using Ingenuity Pathway Analysis (www.
ingenuity.com) to identify signaling connections of the c-Met–
responsive proteins identified here with established regulators of
HGF expression within Ingenuity Knowledge Base, we identified
STAT3 as a potential central node modulating HGF expression in
GBM cells (Figure 6B).
Analysis of our MS data for phosphorylation intensities confirmed
that STAT3 Y705 decreased with c-Met knockdown in U87 cells
and in c-Met knockdown cells that also expressed ΔEGFR (Fig-
ure 6C ), findings that were confirmed by Western blot analysis
(Figure 6D). Additionally, HGF stimulation of U87 and U87 ΔEGFR–
expressing cells lead to increased STAT3 activation (Figure W4, A and B,
respectively). These data show that the activity of STAT3 is also responsive
to the c-Met signal in U87 GBM cells and that it may serve as a key node
regulating HGF.
STAT3 Activity Partially Rescues Loss of c-Met–Dependent
Phenotypes in ΔEGFR-Expressing GBM Cells
Given the strong association between c-Met expression and the
potential regulation of HGF expression by STAT3, we investigated
whether STAT3 activity was necessary for HGF expression. To ad-
dress this, we suppressed STAT3 activity in U87 ΔEGFR cells with
WP1193, a STAT3 phosphorylation inhibitor [41], and found that
HGF mRNA and protein amounts were attenuated (Figure 7A).
Next, we tested whether STAT3 activity can rescue the reduction
of HGF expression in U87 ΔEGFR cells resulting from c-Met
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Figure 4. ΔEGFR regulates HGF expression in an activity-dependent manner. (A) Quantitative real-time PCR analysis of HGF mRNA levels in
U87 cells versus those expressing ΔEGFR (10% FBS–containing media); t test: *P < .05; n = 3 ± SEM; at least duplicate samples per
experiment). (B) Western blots monitored HGF and immunoprecipitated c-Met for pc-Met (Y1234/Y1235) levels in U87 or U87 ΔEGFR cells
(1% FBS–containing media; 20 hours). (C) CM from U87 ΔEGFR cells (1% FBS–containing media; 20 hours) were transferred to 4-hour
serum-starved MDCK cells for the indicated amounts of time, and the levels of c-Met phosphorylation were detected by Western blot.
Additionally, 1% serum–containing media with or without (−) 50 ng/ml rhHGF, or CM that had been pretreated with anti-HGF (0.6 μg/ml)
for 2 hours, were transferred to MDCK cells for 15 minutes. (D) Quantitative real-time PCR analysis of U87 ΔEGFR cells that were either
untreated (−) or treated with 0.1% DMSO, 10 μM AG1478, 10 μM SU11274, or a combination of both SU11274 and AG1478, for 16 hours
in 10% FBS–containing media (t test when compared with the vehicle-treated control: **P < .005, *P < .05; n = 3 ± SEM; samples
were analyzed at least in duplicate per experiment). (E) Western blot analysis of HGF, pEGFR (Y1173), and immunoprecipitated c-Met
for pc-Met (Y1234/Y1235) in U87ΔEGFR cells treatedwith tyrosine kinase inhibitors as in D; 10%FBS–containingmedia (16 hours).
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knockdown. STAT3-CA [42] partially rescued HGF expression in
ΔEGFR-expressing cells lacking c-Met expression both at the
mRNA and protein levels (Figure 7B). To test whether these events
had an impact at the biologic level, we asked whether STAT3-CA
could rescue the suppression of in vitro colony formation associated
with c-Met knockdown in ΔEGFR-expressing cells. Anchorage-
independent growth assays demonstrated that colony formation was
suppressed with c-Met knockdown and that STAT3-CA was not able
to rescue anchorage-independent growth of these cells (Figure 7C ).
These results support our earlier phosphoproteomic and bioinformatic
analyses that STAT3 is a downstream effector of HGF expression in
ΔEGFR-expressing GBM cells. STAT3 likely works in concert
with additional pathways to maximally upregulate HGF expression
(Figure 7D).
Discussion
In GBM, autocrine c-Met/HGF signaling contributes to tumor pro-
gression [26]. We found that the elevated expression of HGF and
c-Met correlated well in a large data set of GBMs, and this was
found predominantly in Mes GBMs. Among the GBM subtypes,
Mes GBMs are associated with a poorer overall survival, with GBM
recurrence [3] and treatment resistance [14], and their gene expres-
sion signatures can predict for this outcome [43,44], allowing for
Figure 5. c-Met is required by ΔEGFR to modulate HGF expression and tumorigenicity. (A) Quantitative real-time PCR measured HGF
mRNA amounts in clonal populations of U87 cells expressing different c-Met shRNA that also expressed ΔEGFR (10% FBS–containing
media; t test: **P < .005, *P < .05; n = 3 ± SEM; at least duplicate samples per experiment). (B) Western blot analysis of HGF levels
present in all cells detailed in A; 10% FBS–containing media. (C) Kaplan-Meier curves of mice that were intracranially injected with 2 ×
105 U87 sh-control, U87 sh-control ΔEGFR, or U87 sh-c-Met clones expressing ΔEGFR. Mice were sacrificed after 65 days. Log-rank
tests determined significant differences between all survival curves compared with the U87 sh-control group; median survival per group
of mice was recorded.
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Figure 6. Identification of STAT3 as responsive to the c-Met signal in U87 GBM cells. (A) PhosphoScan identified phosphotyrosine-
enriched peptides by MS in U87 sh-control, U87 sh-c-Met#B2, U87 sh-control ΔEGFR, and U87 sh-c-Met#B2 ΔEGFR cells. Significant
peptides that differed with c-Met knockdown in parental U87 sh-control cells, and in U87 sh-control ΔEGFR cells, are listed (t test of
matched cells with or without c-Met knockdown: P < .05; n = 2; duplicate samples per experiment). (B) Biologic relationships were
discovered from the list of proteins in A with Ingenuity Knowledge Base’s known modulators of HGF expression. (C) Average abundance
of STAT3 Y705 PhosphoScan analysis signal. (D) Western blot validation of pSTAT3 Y705 phosphorylation in samples used for Phospho-
Scan analysis.
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the possibility that the HGF/c-Met signaling axis is making a con-
tribution to their aggressive phenotype. Although we found that
HGF and c-Met mRNA expression were lower in Cl when com-
pared to Mes tumors, we determined that their coexpression also
correlated significantly in the Cl subtype. Interestingly, Verhaak
et al. [12] identified that the expression of the ΔEGFR was most
frequently found in Cl GBMs (5 of 22 Cl GBMs) and, to a lesser
extent, in Mes and PN GBMs (1 of 38 Mes GBMs and 1 of 37 PN
GBMs), suggesting that in Cl GBMs the connection of these two path-
ways is most critical. Overall, these findings suggest that the c-Met/
HGF axis is an important contributing factor to the oncogenicity of
both Cl and Mes GBM subtypes, with some variations on the exact
triggers for its elevation.
Because both HGF and c-Met are located on chromosome 7,
chromosomal duplication partially account for their increased dosage
in GBM [5]. However, their high expression levels are not likely
Figure 7. STAT3 partially rescues HGF expression and anchorage-independent growth of U87 c-Met knockdown cells. (A) Left panel: Quan-
titative real-time PCRmeasuredHGFmRNA levels in U87ΔEGFR cells treatedwithWP1193 (2.5 μM; 16 hours; 10%FBS–containingmedia).
Untreated (−) and 0.1%DMSO–treated cells were used as negative controls (t test compared with the 0.1%DMSO–treated cells: *P< .05;
n= 3 ± SEM; at least duplicate samples per experiment). Right panel: Western blot analysis showing that WP1193 inhibited pSTAT3 Y705
phosphorylation and HGF expression in cells processed for quantitative real-time PCR analysis. (B) Left panel: Quantitative real-time PCR
analysis of HGF mRNA in U87 ΔEGFR cells expressing combinations of the sh-control, pcDNA3.1-Empty, sh-c-Met#B2, or STAT3-CA
(t test: *P < .05, **P< .005; n = 3 ± SEM; at least duplicate samples per experiment). Right panel: Western blot analysis of HGF and
pSTAT3 (Y705) levels in cell lines represented in the left panel. (C) Anchorage independence of cell lines represented in B (t test: *P <
.05; n = 3 ± SEM; at least duplicate samples per experiment). (D) Proposed model of c-Met signaling regulating HGF expression through
STAT3 or other signaling mechanisms in ΔEGFR-expressing cells.
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accounted for by chromosome 7 trisomy alone. We found that c-Met
signaling increases the expression of its own ligand. c-Met activation
has previously been reported to transcriptionally activate the c-Met
gene [10], highlighting the importance of self-regulation of this signal-
ing axis in GBM. The biologic significance of this pathway is shown
by the impact of reducing c-Met activity on U87 in vitro colony for-
mation and tumorigenicity in xenografts. In agreement with our results,
decreased tumorigenicity occurs when c-Met/HGF–dependent xeno-
grafts are treated with antagonists of c-Met [38] or HGF [9,39]. Taken
together, these data suggest that targeting either c-Met or HGF in
tumors that rely heavily on their autocrine signal for growth and tumori-
genicity may be an effective target for therapeutic intervention, par-
ticularly because of the autonomous autocrine loop that we describe
here. Interestingly, autonomous regulation of the autocrine signal
has also been described for other receptor/ligand pairs, such as for the
EGFR [45] and its cognate ligands, heparin-binding EGF-like growth
factor (HB-EGF), epiregulin, and amphiregulin [46].
In GBM, c-Met is a preferential target of the ΔEGFR [33,34,39].
Our results indicate that the lateral activation of c-Met by ΔEGFR
enhances HGF production, suggesting that targeting HGF could be
beneficial in combination with ΔEGFR-targeted therapies. Studies
have found that antibody-mediated HGF antagonism is effective in
parental U87 or wild-type EGFR-expressing U87 xenografts and not
against U87 xenografts expressing ΔEGFR [39]. This could be due
to the higher levels of HGF expression in ΔEGFR-expressing U87
xenografts that cannot be completely neutralized with anti-HGF
treatment alone. This idea is supported by a significant reduction
in tumor growth when ΔEGFR and HGF antagonists are used in
combination to treat ΔEGFR-expressing U87 xenografts [39]. We
found that c-Met was crucial for ΔEGFR to maintain not only
enhanced HGF levels but also for ΔEGFR-mediated oncogenicity
of U87 cells. Therefore, our data indicate that c-Met may be an
important driver of tumorigenicity for ΔEGFR-expressing GBMs
that are addicted to c-Met/HGF signaling, suggesting that the addi-
tion of therapeutics targeting c-Met to ΔEGFR regimes may prove to
be a more effective treatment strategy.
STAT3 is a master transcriptional regulator of the Mes pheno-
type in GBM [47]. STAT3 signaling is important for HGF/c-Met–
mediated anchorage-independent growth and tumorigenicity [15]
and is a driver of HGF expression in various cancer cell lines [2,48].
Interestingly, we did not find that HGF promoter activity was
attenuated with c-Met knockdown in U87 cells when we evaluated
the first −1029 bp in the 5′ flanking region of the HGF gene, which
contains a cis-acting STAT3 binding element [48] (data not shown).
Another novel finding from our study is that STAT3 signaling
regulated HGF expression in U87 ΔEGFR cells. Interestingly, STAT3
expression predicts poorer outcomes for GBM patients [49], correlating
closely with GBM aggressiveness [49]. Although we found that STAT3
Y705 phosphorylation does not change significantly in response to
ΔEGFR, it is required by ΔEGFR for cellular transformation, prolifer-
ation, and viability [50]. This suggests that ΔEGFR recruits the activity
of STAT3 through signaling intermediates, such as is the case with
c-Met forHGFproduction, tomaintain strengthenedΔEGFR-mediated
tumorigenicity. Our data also suggested that additional signaling
effectors may be required by STAT3 to maximally upregulate HGF
expression in HGF/c-Met–dependent GBM cells expressing ΔEGFR.
In summary, our data highlight the importance of c-Met signaling
for GBM tumorigenesis, the manner in which c-Met upregulates
HGF expression in GBM, and the contribution of ΔEGFR for per-
petuation of the HGF/c-Met signal in GBM. Our data show that
STAT3 is an important component necessary for enhanced c-Met–
mediated HGF expression in ΔEGFR-expressing cells. Additionally,
we have shown that the c-Met/HGF axis is significantly upregulated
in Mes GBMs, indicating that these signals are most important in
this GBM subtype, and by implication represents an opportunity
for therapy of these tumors.
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Figure W1. c-Met and HGFmRNA expression are upregulated in the
Mes GBM subtype. (A) Verhaak et al. [12] classified GBM tumors
into four subtypes (Mes, mesenchymal; PN, proneural; Nrl, neural;
Cl, classical), and c-Met’s expression per GBM was obtained from
the TCGA database (n = 200; Tukey box plot; t test: ***P <
.0001, *P < .05). (B) HGF expression for GBM tumors in A was ex-
tracted from the TCGA database (n = 200; Tukey box plot; t test:
***P < .0001, **P < .005, *P < .05). (C) Affymetrix (U133A format)
gene expression data of GBMs from the National Cancer Institute
(NCI) REMBRANDT database (https://caintegrator.nci.nih.gov/
rembrandt/) was downloaded on 10 May 2011. Gene expression
values were downloaded as log2 transformed, median centered,
quantile data, which were normalized using the Robust MultiChip
Average with a custom Chip Definition File, thereby removing un-
reliable probe set data. Tumors were assigned to GBM subtypes
by z-score normalizing their highest average metagene scores
according to the gene lists described by Verhaak et al. [12] and their
c-Met expression reported (n = 180; Tukey box plot; t test: ***P <
.0001). (D) HGF expression was obtained from the REMBRANDT
database for each GBM as determined in C (n = 180; Tukey box
plot; t test: ***P < .0001, **P < .005). (E) GBMs from the TCGA
database were classified as either Mes, proliferative (Prolif), or PN
based on each tumor’s highest average z-score corrected meta-
gene score from subtype-specific gene lists defined by Phillips et al.
[3]. c-Met’s expression per GBM was downloaded from the TCGA
database (n = 495; Tukey box plot; t test: ***P < .0001, **P <
.005). (F) GBM tumors were classified as in E, and HGF expression
was documented per tumor (n = 495; Tukey box plot; t test: **P <
.005, *P < .05).
Figure W2. Inhibition of c-Met activity in LN18 GBM cells attenuates
HGF expression. Left panel: Quantitative real-time PCR analysis
showing inhibition of HGF mRNA expression in LN18 cells after
treatment with 10 μMSU11274 for 16 hours in Dulbecco’s modified
Eagle’smedium containing 10% FBS (P< .05; t test; n=3; triplicate
samples per experiment). Right panel: Corresponding Western blot
of HGF and pc-Met (Y1234/Y1235) levels after 16-hour treatment
with 10 μM SU11274.
Table W1. Short Tandem Repeat Fingerprinting of U87 and LN18 Cells.
Locus U87 LN18
1 2 1 2
AMEL 105.92 0 110.96 105.81
D3s 1358 134.41 130.52 130.8 126.97
TH01 177.34 0 174.95 0
D13s 317 188.58 176.81 197.34 193.23
D8s 1179 217.23 213.18 230.4 222.22
D7s 820 225.18 221.12 222.03 0
TPOX 268.73 0 269.68 0
D16s 539 294.75 0 300.33 291.74
D18s 51 306.12 0 330.76 322.77
CSF1PO 341.37 337.1 346.35 0
Penta D 433.25 408.85 418.52 0
Penta E 433.77 396.6 412.9 396.98
Cells that were used in preparation of this manuscript were analyzed for their specific marker allele
content using the GenomeLab Human STR Primer Set (Beckman Coulter, Indianapolis, IN). Cell
line isolates may vary between different laboratories, and therefore, these data may be used by other
investigators for comparative purposes.
Figure W3. HGF and c-Met expression correlate in Cl GBM. Four
hundred ninety-five GBMs were classified into subtypes using
gene expression lists defined by Verhaak et al. [12]. The highest
average z-score corrected metagene score was used to establish
each tumor’s subtype. Level 3 HGF and c-Met mRNA expression
data were obtained from the TCGA database, and their expression
levels were correlated in Cl GBMs using Spearman correlation
(n = 141; r = 0.4562; P < .0001).
Figure W4. HGF stimulation of U87 and U87 ΔEGFR–expressing
cells enhances the activity of STAT3. (A) Western blot analysis
of STAT3 activation in U87 cells following 5 minutes of rhHGF
stimulation (50 ng/ml) after 20-hour serum starvation. (B) The
activity of STAT3 was determined in U87 ΔEGFR–expressing cells
after rhHGF stimulation as described in A.
